EMERGENT BIOSOLUTIONS INC (EBS)
Health Care · Biotechnology and Medical Countermeasures · NYSE
Emergent BioSolutions is a biopharmaceutical company providing critical medical countermeasures and life-saving naloxone treatments for global public health threats and emergencies.
What EMERGENT BIOSOLUTIONS INC does
Emergent BioSolutions is a global life sciences company providing medical countermeasures and response solutions for public health threats such as infectious diseases, chemical/biological/radiological hazards, and opioid overdose emergencies. Its business is structured into two reportable segments—Commercial Products (focused on naloxone nasal sprays) and MCM Products (focused on vaccines and therapeutics for anthrax, smallpox, and botulism)—supported by a specialized contract development and manufacturing (CDMO) service capability. The company serves primarily government agencies, including the U.S. government, as well as commercial and international markets.
Recent developments
In August 2026, the company announced an organizational restructuring plan to reduce approximately 90 roles to improve cost structures, alongside the creation of a new Growth organization. It also recently secured significant contract modifications with the U.S. government for ACAM2000 and BAT products and initiated new manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics.
From EMERGENT BIOSOLUTIONS INC's filing of 2026-08-06.
Themes: public health preparedness, biodefense, opioid overdose prevention, vaccines and therapeutics, medical countermeasures, CDMO services, government contracting
Fundamentals
- Price$6.81 as of 2026-10-08 close
- Market cap$349M as of 2026-07-30 (share count; price 2026-10-08)
- 1-year return-31.1% 2025-10-08 close $9.89 → 2026-10-08 close $6.81
- P/En/a negative earnings
- Net margin+7.1% FY2025, SEC XBRL
- Gross margin+30.3% FY2023, SEC XBRL
- ROE+10.1% FY2025, SEC XBRL
- Debt / equity1.10 as of 2026-09-03
- Revenue growth (YoY)-29.9% as of 2026-09-03
- Revenue CAGR (3y)-12.7% SEC XBRL
- Beta1.49 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How EBS compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginbottom 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EMERGENT BIOSOLUTIONS INC looks technically
EMERGENT BIOSOLUTIONS INC (EBS) is trading 20.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 124 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day high about 4 trading days ago. It is 51.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 20.4% below its 200-day average, the long-term trend line — a long-term downtrend | -20.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.11 | $6.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.56 | $8.56 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 5.5. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 124 trading days ago — a "death cross", a bearish long-term signal | 124 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 18.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($6.24 to $7.65) — its "stochastic" reading is 40 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 40.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.06 | $14.06 |
|---|---|---|
| From the 52-week high | it is 51.6% below its 52-week high (its highest price of the past year) | -51.6% |
| Above the 52-week low | it is 56.0% above its 52-week low (its lowest price of the past year) | +56.0% |
| Below the 52-week high | it is 51.6% below its highest point of the past year | 51.6% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 42 trading days ago | 42 sessions |
| All-time high | its highest closing price on record is $137.61 (set on 2020-08-06) | $137.61 |
| Given back of the 52-week move | over the past year its closes ranged ($4.45 to $13.90), and it has recovered roughly a quarter of its fall from last year’s high — 25% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.29 to $10.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.0% |
| From the all-time high | it is 95.1% below its all-time high | -95.0% |
| Nearest price level | it is trading 1.3% above a support level at $6.72 — a price it turned at twice since 2025-05-08, most recently on 2025-07-16. Since 2024-10-08 it has 4 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $1.42 (set on 2024-02-06) | $1.42 |
| Above the all-time low | it is 379.6% above its all-time low | +379.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 30th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3993 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3993 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.18 and $7.25 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.18 – $6.71 – $7.25 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges below its 200-day average price (20.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.8% |
|---|---|---|
| Open gap | it gapped 3.2% above the previous close 3 sessions ago and has not traded back through the level it left behind at 6.33 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.2% |
| Gap filled | a 2.5% gap down opened on 2026-08-10 has been "filled" 35 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 35 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 12.5 percentage points (the stock gained 13.5% while the market gained 1.0%) | +12.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 20.2 percentage points (the stock lost 16.3% while the market gained 3.8%) | -20.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 33.4 percentage points (the stock lost 15.9% while the market gained 17.5%) | -33.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 46.1 percentage points (the stock lost 31.1% while the market gained 15.0%) | -46.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 11.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +4.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.93 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -14.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $5.83 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | +16.9% |
Price levels it has turned at before
EBS last closed at $6.81 on 2026-10-08. Since 2024-10-08 it has turned at 4 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.72 | Support | 1.3% below the last close | turned there twice · 2025-05-08 to 2025-07-16 |
| $6.96 | Resistance | 2.3% above the last close | turned there three times · 2025-05-20 to 2025-06-24 |
| $7.42 | Resistance | 9.0% above the last close | turned there twice · 2025-09-08 to 2026-07-14 |
| $6.17 | Support | 9.4% below the last close | turned there twice · 2025-05-27 to 2025-07-01 |
| $6.03 | Support | 11.5% below the last close | turned there twice · 2025-06-05 to 2025-06-18 |
| $7.69 | Resistance | 12.9% above the last close | turned there 9 times · 2024-11-15 to 2026-08-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $5.50.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 16 trading days, since 2026-09-17.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$11.00 range $10.00 – $12.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EBS
- Consensus EPS estimate-$0.3914 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 from -$0.3914, on 2026-09-03, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on U.S. government procurement contracts for medical countermeasures and the risk of reduced funding or demand for these products.","Reliance on third-party manufacturers for the production of critical drug substances and products, which risks supply chain interruptions and regulatory non-compliance.","Operational challenges and financial instability stemming from the restructuring and turnaround of the naloxone business and ongoing debt management."]
What changed in the latest 10-Q
AI-assisted comparison of EBS's 10-Q filed 2026-08-06 against the prior one filed 2026-05-01.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-06) references prior-period comparison: 'our results for the three and six months ended June 30, 2025 compared to our results for the three and six months ended June 30, 2024' and cites the Quarterly Report for the quarter ended June 30, 2025 filed August 7, 2025.
- Newer filing (2026-08-06) states the Services segment discussion refers to 'Note 16, Segment information' instead of Note 15.
- Newer filing (2026-08-06) describes ACAM2000 as '(Smallpox and Mpox (Vaccinia) Vaccine, Live)' and states it is licensed 'for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection'.
- Newer filing (2026-08-06) uses the trademark symbol for Ebanga ('Ebanga ®') instead of 'Ebanga™'.
- Newer filing (2026-08-06) ends the Share Repurchase Program paragraph with 'During the three and six months ended June 30, 2026, the Company utiliz' (truncated).
- Removed:
- Older filing (2026-05-01) references prior-period comparison: 'our results for the quarter ended March 31, 2025 compared to our results for the quarter ended March 31, 2024' and cites the Quarterly Report for the quarter ended March 31, 2025 filed May 8, 2025.
- Older filing (2026-05-01) describes ACAM2000 as '(Smallpox (Vaccinia) Vaccine, Live)' and states it is licensed 'for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection' (no mpox reference).
- Older filing (2026-05-01) uses 'Ebanga™' instead of 'Ebanga ®'.
- Older filing (2026-05-01) states 'During the three months ended March 31, 2026, the Company utilized $9.1 million to repurchase 0.9 million shares at an avera...' (truncated, present in older version).
- Reworded:
- Prior-period comparison reference changed from the Q1 2025 report (filed 2026-05-01) to the Q2 2025 report (in newer filing filed 2026-08-06).
- Segment information note reference changed from 'Note 15' in the older filing to 'Note 16' in the newer filing.
- ACAM2000 product description changed from smallpox-only to smallpox and mpox indication.
- Ebanga trademark notation changed from ™ to ®.
- Notes:
- Both texts are truncated at the end of the Share Repurchase Program subsection; the newer filing cuts off mid-sentence, and the older filing also appears to cut off mid-sentence.
- Comparison limited to the MD&A text provided; no other sections were available for cross-checking.
Risk Factors
- Added:
- Newer filing (filed 2026-08-06) adds a new risk factor regarding the organizational restructuring plan announced on August 5, 2026.
- Notes:
- The newer filing's Risk Factors section text is truncated at the end ('If we fail to a'), so additional changes after that point, if any, cannot be assessed.
- The older filing's provided text appears to end the Risk Factors section and then include subsequent sections (Item 2, Item 3, etc.), while the newer filing text is limited to Risk Factors with a page number reference (48).
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 30 days · read to 2026-10-050 buys · 2 sells ($145792) — 2 selling insiders
- Last 90 days · read to 2026-10-050 buys · 2 sells ($145792) — 2 selling insiders
- Last 180 days · read to 2026-10-050 buys · 10 sells ($689232) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-07. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EBS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for EBS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding EBS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,867,253
- Reported value $74,316,930
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EBS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EBS had 9,786,380 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
EBS had 19.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.6 days to cover at the same settlement.
- Reported short interest (shares) 9,786,380
- Short interest (% of shares outstanding) 19.1%
- Prior settlement (shares) 10,842,235
- Reported change -9.74%
- Days to cover (reported) 8.6
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bavarian Nordic (BVNRY)
- Hikma Pharmaceuticals
- Adapt Pharma (subsidiary of Emergent)
- SERB Pharmaceuticals
- Ridgeback Biotherapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EBS vs…
EMERGENT BIOSOLUTIONS INC is found in…
EBS ranks in…
Frequently asked questions
What does EMERGENT BIOSOLUTIONS INC (EBS) do?
Emergent BioSolutions is a global life sciences company providing medical countermeasures and response solutions for public health threats such as infectious diseases, chemical/biological/radiological hazards, and opioid overdose emergencies. Its business is structured into two reportable segments—Commercial Products (focused on naloxone nasal sprays) and MCM Products (focused on vaccines and therapeutics for anthrax, smallpox, and botulism)—supported by a specialized contract development and…
What sector is EMERGENT BIOSOLUTIONS INC (EBS) in?
EMERGENT BIOSOLUTIONS INC (EBS) is classified in the Health Care sector. Its industry is Biotechnology and Medical Countermeasures. It trades on NYSE.
Who are EMERGENT BIOSOLUTIONS INC's (EBS) competitors?
Notable peers of EMERGENT BIOSOLUTIONS INC (EBS) include Bavarian Nordic, Hikma Pharmaceuticals, Adapt Pharma (subsidiary of Emergent), SERB Pharmaceuticals and Ridgeback Biotherapeutics. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in EBS?
Yes — we hold 1 matched STOCK Act disclosure for EBS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is EMERGENT BIOSOLUTIONS INC (EBS) overbought or oversold right now?
EMERGENT BIOSOLUTIONS INC (EBS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EBS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.